These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29023827)

  • 1. TNFα and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNFα antagonists.
    Deubelbeiss C; Kolios AGA; Anzengruber F; French LE; Yawalkar N; Kempf W; Kerl K; Meier B; Navarini AA
    J Cutan Pathol; 2018 Jan; 45(1):23-28. PubMed ID: 29023827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics.
    Stoffel E; Maier H; Riedl E; Brüggen MC; Reininger B; Schaschinger M; Bangert C; Guenova E; Stingl G; Brunner PM
    Br J Dermatol; 2018 May; 178(5):1151-1162. PubMed ID: 29143979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor-associated dermatitis.
    Cohen JN; Bowman S; Laszik ZG; North JP
    J Am Acad Dermatol; 2020 Feb; 82(2):430-439. PubMed ID: 31859047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
    Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
    World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
    Joyau C; Veyrac G; Dixneuf V; Jolliet P
    Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical reactions induced by tumor necrosis factor-alpha antagonists: A literature review based on 46 cases.
    Olteanu R; Zota A
    Indian J Dermatol Venereol Leprol; 2016; 82(1):7-12. PubMed ID: 26728803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
    Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of eczematous and vesicular dermatitis during anti-TNFalpha therapy for rheumatoid arthritis.
    Savoia F; Gaddoni G; Casadio C; Spadola G; Patrizi A; Giacomini F; Aldi M
    G Ital Dermatol Venereol; 2011 Aug; 146(4):308-9. PubMed ID: 21785399
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of new-onset psoriasis while on anti-TNFalpha treatment.
    Matthews C; Rogers S; FitzGerald O
    Ann Rheum Dis; 2006 Nov; 65(11):1529-30. PubMed ID: 17038454
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic induction of IL-23 by TNFα, IL-17A, and EGF in keratinocytes.
    Ehst B; Wang Z; Leitenberger J; McClanahan D; De La Torre R; Sawka E; Ortega-Loayza AG; Strunck J; Greiling T; Simpson E; Liu Y
    Cytokine; 2021 Feb; 138():155357. PubMed ID: 33153894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis.
    Vasconcellos JB; Pereira DD; Vargas TJ; Levy RA; Pinheiro GD; Cursi ÍB
    An Bras Dermatol; 2016; 91(5 suppl 1):137-139. PubMed ID: 28300922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.
    de Gannes GC; Ghoreishi M; Pope J; Russell A; Bell D; Adams S; Shojania K; Martinka M; Dutz JP
    Arch Dermatol; 2007 Feb; 143(2):223-31. PubMed ID: 17310002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ameliorative effects of a fusion protein dual targeting interleukin 17A and tumor necrosis factor α on imiquimod-induced psoriasis in mice.
    Liu Z; Liu H; Xu P; Yin Q; Wang Y; Opoku YK; Yang J; Song L; Sun X; Zhang T; Yu D; Wang X; Ren G; Li D
    Biomed Pharmacother; 2018 Dec; 108():1425-1434. PubMed ID: 30372845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.
    Caldarola G; Pirro F; Di Stefani A; Talamonti M; Galluzzo M; D'Adamio S; Magnano M; Bernardini N; Malagoli P; Bardazzi F; Potenza C; Bianchi L; Peris K; De Simone C
    Expert Opin Biol Ther; 2020 Jun; 20(6):665-672. PubMed ID: 32045273
    [No Abstract]   [Full Text] [Related]  

  • 16. Psoriasiform Eruption Secondary to the Use of Adalimumab.
    Esteves PM; Barbalho MG; Cortes JG; Cuzzi T; Sodre CT; Ramos-e-Silva M
    J Drugs Dermatol; 2015 Oct; 14(10):1152-4. PubMed ID: 26461828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study [Formula: see text].
    Cossio ML; Genois A; Jantchou P; Hatami A; Deslandres C; McCuaig C
    J Cutan Med Surg; 2020; 24(4):333-339. PubMed ID: 32527153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.
    Johnston A; Fritz Y; Dawes SM; Diaconu D; Al-Attar PM; Guzman AM; Chen CS; Fu W; Gudjonsson JE; McCormick TS; Ward NL
    J Immunol; 2013 Mar; 190(5):2252-62. PubMed ID: 23359500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.
    Segaert S; Hermans C
    Am J Clin Dermatol; 2017 Dec; 18(6):771-787. PubMed ID: 28597181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.